EW

Edwards Lifesciences Corp

EW, USA

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

https://www.edwards.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
EW
stock
EW

EW Stock Sees Price Target Boost from Citigroup, Maintains Buy R GuruFocus

Read more →
EW
stock
EW

Should You Continue to Hold EW Stock in Your Portfolio? TradingView

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$93.9436

Analyst Picks

Strong Buy

10

Buy

4

Hold

17

Sell

0

Strong Sell

1

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Low

38.01

Low 50

High 10

Price to Book Ratio (P/B)

-

Very High

4.82

Low 1

High 3

Return on Equity (ROE)

-

Very Low

2.85 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

2.19 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

33.24 %

Low 5%

High 15%

Debt to Equity

-

Very High

0.30

Low 1

High 0.3

Investors

* Institutions hold a combined 76.71% of the total shares of Edwards Lifesciences Corp

1.

Vanguard Group Inc

(11.9226%)

since

2025/06/30

2.

BlackRock Inc

(9.4783%)

since

2025/06/30

3.

JPMorgan Chase & Co

(4.5603%)

since

2025/06/30

4.

State Street Corp

(4.3663%)

since

2025/06/30

5.

Wellington Management Company LLP

(3.377%)

since

2025/06/30

6.

Vanguard Total Stock Mkt Idx Inv

(3.1392%)

since

2025/07/31

7.

Bank of New York Mellon Corp

(2.9955%)

since

2025/06/30

8.

Vanguard 500 Index Investor

(2.473%)

since

2025/07/31

9.

Vanguard Mid Cap Index Institutional

(2.2289%)

since

2025/07/31

10.

Citadel Advisors Llc

(2.1685%)

since

2025/06/30

11.

Geode Capital Management, LLC

(2.167%)

since

2025/06/30

12.

Jennison Associates LLC

(1.9879%)

since

2025/06/30

13.

Vanguard Health Care Inv

(1.9064%)

since

2025/06/30

15.

Morgan Stanley - Brokerage Accounts

(1.2765%)

since

2025/06/30

16.

Fidelity 500 Index

(1.2665%)

since

2025/07/31

17.

NORGES BANK

(1.2645%)

since

2025/06/30

18.

Brown Advisory Holdings Inc

(1.2455%)

since

2025/06/30

19.

SPDR® S&P 500® ETF

(1.2096%)

since

2025/08/31

20.

iShares Core S&P 500 ETF

(1.2023%)

since

2025/08/31

21.

Ninety One UK Limited

(1.182%)

since

2025/06/30

22.

Marshall Wace Asset Management Ltd

(1.1745%)

since

2025/06/30

23.

Millennium Management LLC

(1.1381%)

since

2025/06/30

24.

Northern Trust Corp

(1.041%)

since

2025/06/30

25.

Deutsche Bank AG

(1.0243%)

since

2025/06/30

26.

Vanguard Value Index Inv

(0.8856%)

since

2025/07/31

27.

JPMorgan US Equity L

(0.8463%)

since

2025/07/31

28.

Vanguard Mid-Cap Growth ETF

(0.8345%)

since

2025/07/31

29.

Wellcome Trust Ltd

(0.8176%)

since

2025/06/30

30.

Holocene Advisors, LP

(0.8012%)

since

2025/06/30

31.

The Health Care Select Sector SPDR® ETF

(0.6823%)

since

2025/08/31

32.

Vanguard Institutional Index I

(0.6039%)

since

2025/07/31

33.

BGF World Healthscience A2

(0.5937%)

since

2025/05/31

34.

Harbor Capital Appreciation Instl

(0.5575%)

since

2025/06/30

35.

State St S&P 500® Indx SL Cl III

(0.5333%)

since

2025/08/31

36.

UniGlobal Vorsorge

(0.4595%)

since

2025/07/31

37.

Ninety One Global Franchise

(0.4417%)

since

2025/03/31

38.

Ninety One GSF Glb Frchs I Acc USD

(0.4417%)

since

2025/05/31

39.

iShares US Medical Devices ETF

(0.4339%)

since

2025/08/31

40.

Fidelity Select Medical Tech and Devcs

(0.4292%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.6118

Latest Release

Date

2025-09-30

EPS Actual

0.67

EPS Estimate

0.5942

EPS Difference

0.0758

Surprise Percent

12.7566%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5.5)
Defensive
Highly Defensive(8.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(8.3)
GARP
Fair GARP(4)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(4.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
High Quality(8)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.